What is Charm Therapeutics?
Charm Therapeutics is at the forefront of developing next-generation precision oncology treatments, leveraging a proprietary AI-driven drug discovery platform. The company's lead program targets acute myeloid leukemia (AML) with a novel menin inhibitor. This strategic focus on AI in drug development positions Charm Therapeutics to potentially revolutionize cancer treatment by identifying and advancing highly targeted therapies. The company's commitment to innovation in a critical area of unmet medical need is a key driver of its market appeal.
How much funding has Charm Therapeutics raised?
Charm Therapeutics has raised a total of $147.3M across 3 funding rounds:
Series A
$50M
Series B
$80M
Private Equity
$17.3M
Series A (2022): $50M with participation from F-Prime Capital, General Catalyst, and OrbiMed
Series B (2025): $80M led by New Enterprise Associates, OrbiMed, F-Prime Capital, and SR One
Private Equity (2025): $17.3M, investors not publicly disclosed
Key Investors in Charm Therapeutics
F-Prime Capital
F-Prime Capital is a venture capital firm established in 2002, dedicated to investing in healthcare and technology. They provide a team of investors, engineers, doctors, and scientists to support portfolio companies.
General Catalyst
General Catalyst is a venture capital firm that identifies and supports transformational business opportunities across multiple sectors and stages, backing entrepreneurs with ambitious visions.
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
What's next for Charm Therapeutics?
With the recent influx of capital, Charm Therapeutics is poised for accelerated growth and the advancement of its therapeutic pipeline. The major strategic investment, likely a Series B round given the context, suggests the company is moving towards later-stage development and potential commercialization efforts. This funding will enable Charm Therapeutics to further refine its AI platform, expand its research and development capabilities, and potentially initiate or progress clinical trials for its lead AML program. The backing from prominent investors indicates a strong belief in the company's scientific foundation and its potential to deliver impactful treatments.
See full Charm Therapeutics company page
